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Abstract 
It is now well established that the prime trigger to blood coagulation in vivo is tissue factor 
(TF) that is exposed on the surface of fibroblasts as a result of vessel wall injury. TF joins 
activated factor VII (FVIIa) normally present in the circulating blood and the TF-FVIIa 
complex converts FX to FXa. TF activity and the extrinsic pathway of blood coagulation in 
general are regulated by the specific and major physiological circulating inhibitor: "tissue 
factor pathway inhibitor -TFPI”. TFPI binds to factor Xa and, in this combination, binds to and 
inhibits tissue factor/factor VIIa complex and activated FX (FXa) and thus TFPI is currently 
being included as a natural coagulation inhibitor. 
TFPI is synthesized primarily by the vascular endothelium.. TFPI is distributed in three pools 
in vivo; about 80 to 85% of the total body TFPI is associated with endothelial cell-surface, 
presumably involving glycosaminoglycans and proteoglycans and 15-20% is blood-born 
circulating in plasma, of which 80% bound to lipoproteins and the rest is the free form, and a 
tiny proportion (~3%) is found in platelets. The TFPI that is free in plasma is the 
physiologically active anticoagulant part of TFPI. The importance of TFPI as a natural 
coagulation inhibitor is reflected by the  role TFPI plays in several diseases, as detected by its 
plasma levels, presence of  TF and TFPI in pathologic specimens as well as the effect of 
exogenously administered recombinant TFPI (rTFPI) on thrombosis, in both humans and 
animal models. Recent literature is reviewed on the involvement of TFPI in diseases like: 
Atherosclerosis, arterial thrombosis, Restenosis following arterial intervention, Stroke and ischemia 
reperfusion injury, Deep Venous Thrombosis (DVT) and anti-phospholipid antibody syndrome, Acute 
Lung Injury, Malignancy particularly the metastasis of tumor cell, Chronic renal failure (CRF), 
nephrotic syndrome, crescentic glomerulonephritis, and thrombosis associated with paroxysmal 
nocturnal hemoglobinuria (PNH). Lastly, a short account is added on the potential 
Therapeutic Uses of TFPI. 
Conclusion  
This review article aims to highlight the importance of yet another natural coagulation 
inhibitor (TFPI), like earlier inhibitors, its deficiency in numerous disease conditions led to the 
elaboration of recombinant TFPI (rTFPI) which holds much promise in the future therapy of 
thrombotic disease.  
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Introduction 
 The Coagulation Mechanism 
nder normal conditions the blood 
circulates freely within the confines of 
the vascular system. However, when blood 
escapes to extravascular sites after blood 
vessel injury or the vessel wall becomes 
pathologically challenged by atheroma, 
haemostasis may be activated ending in the 
formation of blood (fibrin) clot. This process 
is finely regulated by positive and negative 
feedback loops that control fibrin clot 
formation.  
For many decades the accepted blood 
coagulation mechanism has been based on 
the concept of the coagulation cascade model 
(Figure 1) that describes the interactions of 
the coagulation factors along two pathways: 
the intrinsic pathway which is triggered by 
the contact of blood with a foreign surface, 
and the extrinsic pathway which is triggered 
by exposure of the blood to the 
transmembrane receptor tissue factor (TF) 
which binds to clotting factor VIIa to form 
TF/FVIIa complex. Both pathways meet at 
the level of clotting factor X after which the 
common pathway progresses until the 
generation of the thrombin and the 
formation of fibrin clot. However, while the 
cascade model delineates the interactions 
between the coagulation proteins and 
provides a framework for interpreting the 
common screening coagulation tests 
(particularly the PT and the APTT), it is 
gradually been realized that the cascade 
model suffers from many limitations, as it 
fails to explain convincingly how hemostatic 
activation occurs in vivo. For example, the 
model cannot explain why hemophiliacs 
bleed when they have an intact factor 
VIIa/TF "extrinsic" pathway.   
The classical cascade model of the coagulation 
mechanism is being replaced by the new, 
Cell-based model of coagulation 1 (Figure 2) 
which emphasizes the interaction of 
coagulation proteins with the cell surfaces of 
platelets, subendothelial cells and the 
endothelium. According to this model   
coagulation is initiated (The Initiation Phase) 
by the formation of a complex between 
tissue factor (TF) exposed on the surface of 
fibroblasts as a result of  vessel wall injury, 
and activated factor VII (FVIIa), normally 
present, in tiny quantities, in the circulating 
blood. The TF-FVIIa complexes convert FX 
to FXa on the TF bearing fibroblasts. FXa 
then activates prothrombin (FII) to thrombin 
(FIIa). The next phase is the Amplification 
Phase in which this limited amount of 
thrombin activates FVIII, FV, FXI and 
platelets, on the surface of blood platelets. 
Thrombin-activated platelets change shape 
and as a result will expose negatively 
charged membrane phospholipids, which 
form the perfect template for the assembly 
of various clotting factors and full thrombin 
generation, involving FVIIIa and FIXa (The 
Propagation Phase). 
 
Intrinsic Pathway Extrinsic pathway
FXII         FXIIa
FXI           FXIa
FIX             FIXa
X                 Xa
Tissue factor
Factor VIIa
& Ca ++
FVIIIa
Prothrombin              Thrombin
FVa+ Ca+P
Fibrinogen Fibrin
Tissue Factor pathway
Inhibitor (TFPI)
 
Figure 1: The coagulation cascade 
U 
Tissue Factor Pathway Inhibitor 
 
3 
J T U Med Sc 2009; 4(1) 
 
Figure 2: The coagulation cascade model 
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Figure 3: The Coagulation inhibitors 
 
 
According to this cell-based model the tissue 
factor (TF) extrinsic pathway is the principal 
cellular initiator of normal blood 
coagulation in vivo, and the major regulator 
of haemostasis and thrombogenesis, with 
the intrinsic pathway, playing an 
amplification role 1, 2.   
 
Inhibition of the Coagulation System – 
Tissue Factor Pathway Inhibitor - TFPI 
In vivo TF activity and the extrinsic pathway 
of blood coagulation is regulated by the 
specific and major physiological circulating 
inhibitor known as "tissue factor pathway 
inhibitor (TFPI). TFPI binds to factor Xa and, 
in this combination, binds to and inhibits 
tissue factor/factor VIIa complex 2, 3.  Many 
pieces of recent evidence in human and 
animal studies2 indicated that the deficiency 
of this inhibitor can lead not only to a 
thrombotic tendency but also to the 
development of atherosclerosis.  Thus TFPI 
is currently being included as a natural 
coagulation inhibitor.  
Prior to 1983, two major mechanisms were 
known for controlling blood coagulation.  
One is the inhibition of the serine proteases 
(factors XIa, IXa, Xa and thrombin) by 
antithrombin and the other is the inactivation 
of two key cofactors (factors Va and VIIIa) by 
the activated protein C/protein S complex 4 
(Figure 3).  Although antithrombin has been 
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shown to inhibit VIIa/TF in vitro 5, 6 it does 
not appear to play a major role in inhibiting 
VIIa/TF in vivo 7, 8. Thus neither of the above 
two mechanisms controls the initiation of TF-
induced coagulation.  There were earlier 
indications that an inhibitor of VIIa/TF 
complex may be present in serum; however, 
compelling evidence for a third inhibitory 
mechanisms, eventually identified as TFPI, 
was not discovered until 1983, in Rapaport’s 
laboratory 9.  This inhibitor which blocks 
VIIa/TF induced coagulation requires factor 
X/Xa as a cofactor for its functionality 9, 10.    
 
Synthesis of TFPI 
TFPI is synthesized primarily by the vascular 
endothelium under normal physiologic 
conditions 11.  In immunohistochemical 
analysis of normal human tissues, TFPI was 
present primarily in the microvascular 
endothelial surface and megakaryocytes 12,13; 
but can also located on the surface of 
monocytes 14 within platelets 15 and 
circulating in plasma 16,17. Studies of cultured 
endothelial cells have demonstrated that 
TFPI associated with the cell surface through 
a glycophosphatidylinositol (GPI)-anchor 18, 
in a manner that is not dependant on 
glycosaminoglycans (GAGs) or altered by 
heparin 19, 20.  These results indicate that TFPI 
is a GPI-anchored protein.  In addition, 
heparin releasable-TFPI likely represents 
only a small portion of the total TFPI on 
endothelium that remains attached to cell 
surface glycosaminoglycans after cleavage of 
the GPI-anchor by endogenous enzymes 20. 
 
Distribution of TFPI 
TFPI is distributed in three pools in vivo; 
about 80 to 85% of the total body TFPI is 
bound toendothelial cell-surface, presumably 
involving glycosaminoglycans and 
proteoglycans, and 15-20% is blood born, 
circulating in plasma, of which 80% is bound 
to lipoproteins and the rest is the free form; a 
tiny proportion (~3%) is found in platelets 21, 
22. The TFPI that is free in plasma (free form) 
is the physiologically active anticoagulant 
part of TFPI 2, while the TFPI associated with 
plasma lipoproteins is C-terminally 
truncated and is a less efficient anticoagulant 
22. Intravenous administration of heparin 
results in a 2- to 4- fold increase in plasma 
TFPI levels from the release of the 
endothelial GPI bound full-length TFPI 23, 
which is known to have more potent 
anticoagulant effect than circulating 
lipoprotein- associated TFPI 24, 25. These 
observations might account for some of the 
anticoagulant effect of heparin. 
There is now convincing evidence from in 
vitro and in vivo experiments that TFPI plays 
an important role in regulating the initiation 
of blood coagulation 7, 8, 26-29.  In man, some 
studies reproted that low levels of TFPI are a 
weak risk factor for venous thrombosis 30-33.  
However, manifest TFPI-deficiency, either 
associated or not with thrombotic disorders, 
similar to deficiencies of other coagulation 
inhibitors, have not yet been detected 34. One 
possible explanation for this apparent 
discrepancy between the experimental 
evidence and data in humans could be the 
available TFPI assays, at the time the studies 
were undertaken, were technically 
inadequate to detect the role of TFPI in vivo 
and thus to detect TFPI deficiency 33, 34. 
 
Role of TFPI in Disease 
The role TFPI plays in several disease states 
has been uncovered by measurement of its 
plasma levels, presence of  TF and TFPI in 
pathologic specimens as well as the effect of 
exogenously administered recombinant TFPI 
(rTFPI) on thrombosis in animal models 3.  
Measurements of TFPI levels in several 
disease states have demonstrated either a 
deficiency state due to consumption or 
elevated levels indicating endothelial injury 
or inflammation.  However, since ~85% of 
TFPI is bound to the endothelium, the 
plasma levels of TFPI do not accurately 
reflect the total body TFPI levels 12.  
 
TFPI Deficiency and Arterial and Venous 
Thrombosis 
TFPI null humans have not been identified 
suggesting that TFPI is required for human 
birth and reproduction.  However, low 
plasma levels of TFPI are weakly linked to 
disease in humans  and several studies have 
suggested that plasma TFPI levels may 
indicate a “threshold effect”, where patients 
with free (non-lipoprotein bound) plasma 
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TFPI concentration less than 10% of the 
normal mean value, are at increased risk (~ 
2-fold) for both deep venous thrombosis and 
myocardial infarction35-38.  In other published 
studies there is a considerable amount of 
conflicting data about the contribution of 
plasma TFPI levels and the development of 
thrombosis39-42.  This is likely a result of the 
wide normal range of plasma TFPI43, the 
various methods for measurement of plasma 
TFPI44 and the poor correlation between the 
soluble circulating plasma TFPI 
concentration and the amount of cell surface 
associated   endothelial   and/or   platelet  
TFPI43.   
 
Atherosclerosis and arterial thrombosis   
The disruption of atherosclerotic plaque in 
coronary arteries is usually complicated by 
acute local thrombosis which leads to 
unstable angina and myocardial infarction 45.  
Such event of disruption exposes the 
monocyte/macrophage TF in these plaques 
46, 47 to circulating blood, resulting in the 
formation of a mural thrombus.  However, 
TFPI colocalized with TF in endothelial cells, 
macrophages, and vascular smooth muscle 
cells plays a regulatory role in TF-induced 
thrombosis in atherosclerotic plaques 48-51.  
Under culture conditions macrophages 
exposed to cholesterol and oxidized LDL 
upregulate TF but not TFPI, create a 
procoagulant state which may end in 
thrombus formation52.  Some studies have 
shown that arterial thrombi formed on 
ruptured atherosclerotic plaques were 
resistant to heparin and aspirin53, but a 
beneficial effect of recombinant TFPI on TF-
induced arterial thrombosis have been 
demonstrated by others54-57. rTFPI 
administered in a model of dog coronary 
artery with intimal injury, maintained 
coronary patency following fibrinolysis 55. 
This finding is of particular interest since the 
current use of aspirin and heparin after 
thrombolysis is only partially effective in 
preventing recurrent thrombosis and leaves 
a potential useful antithrombotic role for 
TFPI in the management of coronary 
thrombosis. 
In this respect it is worthwhile adding that in 
rabbits and pigs significant reduction in the 
degree of restenosis at the site of balloon-
induced arterial injury was shown following 
the inhibition   of   local   thrombosis   with  
rTFPI 59, 60.  
 
Acute coronary syndromes 
A hypercoagulable state exists in patients 
with acute coronary syndrome, whether 
myocardial infarction (MI) or unstable 
angina(US), as depicted by the elevated 
levels of prothrombin fraction 1+2, thrombin 
antithrombin complexes, and D-Dimer as 
well as plasminogen activator inhibitor 
(PAI) and  reduced levels of the natural 
coagulation inhibitors protein C and 
antithrombin. However, the reduction in the 
level of these two natural coagulation 
inhibitors is compensated for by the 
significant elevation in plasma levels of both 
total and free plasma TFPI in MI and UA61.  
This was taken to be a physiological 
response towards maintaining the balance 
of procoagulant versus anticoagulant 
activities that prevents further development 
of thrombosis. 
 
Ischemia-reperfusion injury and stroke 
Activation of TF-induced coagulation plays 
an important role in ischemia reperfusion 
injury which complicates shock, central 
nervous system thrombosis and following 
surgery of the liver, spinal cord, brain, lungs, 
etc. 62, 63.  In a study using a rabbit model of 
ischemia-reperfusion injury of the spinal 
cord, rTFPI-treated animals showed 
significant recovery of neurologic function, 
compared with those treated with heparin 
alone64. Similarly, rTFPI also protected rats 
against the hepatic ischemia reperfusion 
injury65. These observations show clearly 
that TFPI plays an important potential 
protective role in ischemia reperfusion injury 
and stroke. 
 
Thrombosis associated with use of oral 
contraceptives 
The plasma TFPI concentration decreases 
about 25% in women using oral 
contraceptives and this represents increased 
risk (up to 6-fold) of thrombosis associated 
with the use of oral contraceptives66-70.  In 
animal models the decreased TFPI in the 
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presence of FV Leidin (FVL) enhances 
further the risk of thrombosis.  It has been 
found that mice with heterozygous 
deficiency of TFPI develop normally and do 
not suffer from spontaneous thrombosis 71; 
however, when the FVL mutation is bred 
into such mice, the animal develops severe 
disseminated thrombosis and death 72.  These 
studies in genetically alerted mice support 
the notion that decreased TFPI contributes to 
increased risk for thrombosis associated with 
oral contraceptive use. 
 
Deep Venous Thrombosis (DVT) 
A convincing association between TFPI and 
venous thrombosis has not been established 
yet. The plasma TFPI levels reamin unaltered 
in DVT 73.  Also low plasma levels of free 
TFPI appear to cause a significantly increase 
in the risk for DVT especially in patients 
with factor V Leiden mutation 74.  In both 
arterial and venous thrombosis, associated 
with antiphospholipid syndrome (APS), the 
free plasma and monocyte TF levels have 
been found to be elevated 75; however, 
Amengual et al 75 also found higher plasma 
TFPI levels in patients with APS.  Similarly, 
in another study, the plasma TFPI activity 
were found to be higher in patients with 
APS, both before and after  intra-venous 
heparin injection; however, the TFPI 
anticoagulant activity was inhibited in the 
presence of lupus anticoagulants 76.  These 
authors suggest that the increased plasma 
TFPI levels may be in response to the 
increased procoagulant TF activity. 
Since plasma TFPI levels reflect only a small 
pool of the total TFPI, Mannuci and co-
workers measured the larger endothelium-
bound and heparin releasable pool of TFPI in 
patients with arterial and venous thrombosis 
77. As compared to normal, the post-heparin 
TFPI levels were found to be significantly 
decreased in 12 out of 113 subjects. Since at 
least one first degree relative had low TFPI 
levels in six cases, it appears that this defect 
could have been inherited.  However, 
whether or not low heparin-releasable 
plasma TFPI plays a definite causative role in 
arterial or venous thrombosis could not be 
established. 
   
Disseminated Intravascular Coagulation 
(DIC) and Sepsis 
TF expression of TF on monocytes 78 and 
endothelium can readily be triggered by 
endotoxemia 79 which I turn ends in DIC. 
Considerable variability exists in the 
reported levels of free TFPI antigen, TFPI 
activity and Xa-TFPI complex in patients 
with DIC 80-82, thereby reducing the 
diagnostic value of measuring these 
parameters in clinical DIC.  In the animal 
models, inhibition of endotoxin-induced 
coagulation was demonstrated, including 
inactivation  of  factor  VIIa,   two-domain  
rTFPI 83.  In a model of E coli sepsis with 
DIC, Creasy et al demonstrated a significant 
decrease in intravascular coagulation, shock 
and mortality with the administration of 
rTFPI 84.  The decrease in mortality with 
rTFPI and inactive VIIa was attributed to the 
reduction of plasma IL-6 and IL-8 85- 87 levels.  
This anti-inflammatory effect of rTFPI was 
attributed, in part, to its ability to prevent 
binding of endotoxin to its cells surface 
receptor, CD14 88. 
 
Acute Lung Injury 
In acute lung injury (ALI) coagulation was 
shown in both the intravascular and 
extravascular compartments in the lung 89, 90.  
Besides, an increased activity of TF pathway 
of coagulation has been demonstrated in the 
alveolar compartment 90.  Since endothelial 
injury with increased vascular permeability 
is the hallmark of ALI, not surprisingly the 
plasma levels of plasma TFPI levels in ALI 
were found to be significantly elevated and 
this was related to endothelial injury in this 
disease 91, 92. 
 
Malignancy and tumor metastasis 
It is now well established that venous 
thromboembolism is a frequent complication 
of cancer.  This appears to be due to the 
shedding of the procoagulant TF into the 
circulation 93, 94 from numerous malignant 
tumors 95, 96 resulting in the activation of the 
extrinsic pathway of coagulation 97.  A 
hypercoagulable state ensues despite 
elevations in the plasma TFPI activity and 
antigen in patients with acute 
nonlymphocytic leukemias with DIC and 
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also in solid tumors 98. Besides its 
procoagulant activity, TF appears to play a 
new role in tumor metastasis.  In melanoma 
cells, the expression of TF correlates with 
hematogenous metastasis 99.  Also melanoma 
cells are rendered less invasive by an anti-TF 
antibody 100.  This action of TF is thought to 
be independent of the role of TF in 
coagulation 100.  In this respect tumor cells 
adhesion and subsequent migration were 
found to be enhanced by binding of TFPI to 
the extracellular domain of TF101.  An 
alternative mechanism by which TFPI may 
promote invasion and metastasis of cancer 
cells could involve inhibition of other serine 
proteases known to help cellular migration 
on the extra cellular matrix 102. In addition to 
promoting metastasis, TF has also been 
implicated the organization and integrity of 
the vessel wall during angiogenesis in a 
hemostasis independent manner 103.  In this 
capacity TF has been found to play a 
significant role in tumor associated 
angiogenesis 104.  This raises the possibility 
that inhibition of TF via TFPI may help 
regulate angiogenesis.  
 
TFPI and Renal Disease  
Both FVIIa and TF were found to be elevated 
in plasma of patients with chronic renal 
failure (CRF) 105, 106.  This is also accompanied 
by elevations in plasma TFPI levels, possibly 
secondary to such factors as administration 
of heparin during hemodialysis as well as 
endothelial injury.  Both TF and TFPI antigen 
have been detected in crescentic 
glomerulonephritis 107.  Also, TFPI has been 
correlated with chronicity in the crescentic 
lesions in this study 107.  Thus, CRF seems to 
be associated with increased TF and TFPI in 
plasma and at the site of inflammation in 
renal tissue. 
 
Childhood Nephrotic Syndrome 
In a recent report on childhood nephrotic 
syndrome 108, both total and free plasma 
TFPI were found to be significantly elevated 
in nephrotic children in the relapse of 
nephrosis with and without steroid 
treatment as well as in those in remission 
while on steroid therapy. However, the 
highest levels of both total and free TFPI 
were recorded in the steroid-resistant 
nephrotics. This study concluded that the 
elevated levels of both total and free TFPI in 
these phases of nephrotic syndrome, 
constitutes, besides the already reported 
elevated levels of proteins C and S 109, 
additional physiological natural 
anticoagulant mechanism, which will 
attenuate the hypercoagulability that 
characterize childhood nephrotic syndrome 
and in this way will guard against the 
thrombosis that is known to be associated 
with nephrotic syndrome. 
 
Treatment of Bleeding in Patients with 
Haemophilia 
In the introduction of this review and in 
relation to the emergence of the cell-based 
model of coagulation the following question 
was raised: if TF-FVIIa is the primary 
initiative of blood clotting in vivo and is a 
potent activator of FX, why do 
haemophiliacs bleed? The discovery and 
characterization of TFPI activity offers new 
hope for better management of 
haemophiliacs 110. In vitro evidence has 
demonstrated that reduction of the 
inhibitory effect of TFPI is an important step 
for the prevention of bleeding in patients 
with haemophilia 111.  Besides, anti-TFPI 
antibody shortens the bleeding time in 
rabbits with antibody-induced haemophilia 
A 112.  In patients with hemophilia, the 
success of recombinant FVIIa therapy in 
those with acquired inhibitors of FVIII or FIX 
has demonstrated that TF pathway is an 
important target for treatment, and suggests 
that therapeutic modulation of TFPI activity 
could be an attractive therapeutic target of 
the development of new therapies to prevent 
bleeding in patients with haemophilia. 
 
Thrombosis Associated with Paroxysmal 
Nocturnal Haemoglobinuria (PNH) 
PNH is a disease characterized by lack of 
glycosyl phosphatidylinositol (GPI)-
anchored protein expression and patients 
with PNH have a pronounced predisposition 
to intravascular thrombosis.  The thromboses 
occur in an organ specific pattern, mostly in 
the portal circulation (hepatic vein occlusion, 
also called the Budd-Chaiari Syndrome, or in 
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venous circulation of the brain 113.  As stated 
earlier, TFPI is an endothelial GP-anchored 
protein and defective expression of TFPI in 
patients with PNH is believed to contribute 
to the organ specific thrombosis observed in 
PNH 114. 
 
Pregnancy Hypertension (PH) 
In a recent study employing precise ELISA 
assays of total and free plasma TFPI 115, the 
levels of total plasma TFPI im normal 
pregnancy was found to be comparable to 
non-pregnant levels; however, the levels of 
free TFPI exhibited significant reduction in 
normal pregnancy as compared to non-
pregnant controls.  The same study has 
found a significant increase in the levels of 
free tissue factor pathway inhibitor (TFPI) in 
pre-eclampsia and in non-proteinuric 
hypertension, as compared to normal 
pregnancy. In pre-eclampsia the elevated 
levels were maintained after placental 
delivery.  Free protein S levels in pre-
eclampsia, non-proteinuric hypertension 
and in post-partum pre-eclamptic patients, 
were significantly higher than in normal 
pregnant controls. Total TFPI fluctuations 
were unremarkable. This study concluded 
that the significant increase in the levels of 
the physiologically active free forms of the 
two coagulation inhibitors, TFPI and protein 
S, in PH, may protect such patients from the 
risks of haemostatic activation which is a 
known feature of PH.  
 
Potential Therapeutic Uses of TFPI 
The inhibition of the extrinsic TF-FVIIa by 
TFPI, as detailed in this review, provided a 
unique therapeutic approach for prophylaxis 
and/or treatment in a wide range of 
pathological conditions. The available 
experimental and clinical data suggest 
strongly that TFPI might turn out to be an 
important treatment for several clinical 
conditions. In particular, TFPI is expected to 
inhibit the development of post-injury 
intimal hyperplasia and thrombotic 
occlusion in atherosclerotic vessels as well as 
being effective in acute coronary syndromes, 
particularly unstable angina and myocardial 
infarction, sepsis and DIC and many more 
conditions116, 117. Strong hope is attached to 
the possible future use of rTFPI in the 
management of acute coronary syndrome, 
particularly the prevention of restenosis after 
angioplasty in humans. In a very recent 
study rTFPI irrigation was shown to inhibit 
thrombosis and neointimal hyperplasia, and 
attenuate vascular remodeling and luminal 
stenosis 118.   
Recombinant TFPI (rTFPI) which has been 
employed in various therapeutic trials is 
available in two forms that differ in their 
pharmacokinetics 84, 119: a full-length protein 
as well as a C-terminally truncated two-
domain form. A Phase II trial of the efficacy 
of TFPI in patients with severe sepsis 
showed a mortality reduction in TFPI- 
compared to placebo-treated patients and an 
improvement of organ dysfunctions. High 
concentrations of TFPI are provided at sites 
of tissue damage and ongoing thrombosis, 
either by exogenous administration of rTFPI, 
or TFPI can be released from intravascular 
stores by heparin and low molecular weight 
heparins (LMWH) 116.  
In a recent study in rabbits and rats, 
intravenous injection of recombinant TFPI-2 
prevented the development of 
experimentally-induced retinal degenerative 
diseases, suggesting the potential use of 
rTFPI in the treatment of retinal 
degeneration in humans 120. Lastly, a recent 
review summarized the evidence, drawn 
from animal models, for the antiangiogenic 
and antimetastatic effects of TFPI and 
described its mechanisms of action 
particularly the potential antitumor 
properties of rTFPI (TFPI-2), thereby 
strengthening the rationale for considering 
TFPI as a future anticancer agent 121. 
These and other pieces of evidence indicate 
clearly that it will not be too long before 
TFPI and its various recombinant forms will 
undergo further development and 
improvement and find multiple therapeutic 
uses in humans. 
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